Clinical Trials Browser

Phase 4 × Gastro-enteropancreatic neuroendocrine tumor × Clear all

NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Phase 4 Completed

42 enrolled 11 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT05701241 2024-06-14

SAUNA

Phase 4 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

Phase 4 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia